The trusted source for
healthcare information and
FDA orders Baxter to recall infusion pumps
Use of pumps allowed during transition
The Food and Drug Administration (FDA) sent a letter to Baxter Healthcare Corp. on April 30 ordering the company to recall and destroy all of its Colleague Volumetric Infusion Pumps in use in the United States. This action is based on a longstanding failure to correct many serious problems with the pumps. The FDA believes there might be as many as 200,000 of those pumps in use.
Additionally, the FDA is ordering the company to provide refunds to customers or replace pumps at no cost to customers help defray the cost of replacement.
The FDA has advised providers that they may continue to use Colleague pumps while it works with the company to develop an "orderly transition plan." Users of Baxter's Colleague pumps will be receiving further instruction and information from Baxter and the FDA regarding their transition.
The FDA has been working with Baxter since 1999 to correct numerous device flaws. Since then, Colleague pumps have been the subject of several Class I recalls for battery swelling, inadvertent power off, service data errors, and other issues.
In June 2006, the FDA obtained a consent decree of permanent injunction in which Baxter agreed to stop manufacturing and distributing all models of the Colleague pump until the company corrected manufacturing deficiencies and until devices in use were brought into compliance. Since then, Baxter has made numerous changes to the Colleague pumps, but these changes have not corrected the product defect leading to the permanent injunction, according to the FDA.
On April 8, 2010, Baxter submitted a proposed correction schedule to the FDA that stated that Baxter did not plan to begin the latest round of corrections to the adulterated and misbranded pumps until May 2012. The proposal also stated that Baxter does not anticipate completion of the proposed corrections until 2013. On that schedule, a device with known safety concerns would remain in use on patients needing specialized care until 2013. FDA found this proposal unacceptable. The 2006 consent decree gave FDA authority to take any action it deemed appropriate. The FDA has determined that this action is necessary, as Baxter has failed to adequately correct, within a reasonable timeframe, the deficiencies in the Colleague infusion pumps still in use.
Therefore the FDA is now ordering Baxter to:
recall and destroy all Colleague infusion pumps;
reimburse customers for the value of the recalled device;
assist in finding a replacement for these customers. (For more information, visit the "Questions and Answers" posted at www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm210768.htm.)
Infusion pumps, including the Baxter Colleague models, have been the source of persistent safety problems. In the past five years, the FDA has received more than 56,000 reports of adverse events associated with the use of infusion pumps. Those events have included serious injuries and more than 500 deaths. Between 2005 and 2009, 87 infusion pump recalls were conducted to address identified safety concerns, according to FDA data.
An FDA analysis of these adverse events has uncovered software defects, user interface problems and mechanical and electrical failures. Problems with infusion pumps are not confined to one manufacturer or one type of device. The most common types of reported problems have been related to software defects, including failures of built-in safety alarms; user interface issues, such as ambiguous on-screen instructions that lead to dosing errors; and mechanical or electrical failures, including components that break under routine use, premature battery failures, and sparks or pump fires.
Failures of infusion pumps have been observed across multiple manufacturers and pump types. The FDA says that many of the reported problems appear to be related to deficiencies in device design and engineering.
In response, last month the FDA announced a new initiative. As part of its initiative, the FDA is moving to establish additional premarket requirements manufacturers will be expected to meet, in part through static testing in FDA's facilities before device submissions.